Japan’s Takeda Pharmaceutical Company Ltd has announced plans to acquire the Belgium-based cell therapy company TiGenix NV for €520 million, a company with which it already has a licensing deal for the company’s lead product. ---Subscribe to MedNous to access this article--- Regenerative Medicine Company News Finance, Grants, Deals
